Stocks › HALO
Halozyme Therapeutics Inc (HALO) stock analysis
WEAK BUY 25% confidence · analysed Oct 13, 2026
On Oct 13, 2026, our model rated Halozyme Therapeutics Inc (HALO) WEAK BUY with 25% confidence at a price of $111.99. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 41. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.6x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $82.22 and the swing low is $61.33; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of 24.9% and revenue growth of +47.7%.
In its latest quarter it earned $2.28 per share, which beat the $1.82 analysts expected, with revenue +47.7% year over year.
Wall Street's average rating is 1.7 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $101.75.
The next earnings report is expected around Nov 2, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $111.21, a target of $116.94 (+5.2%) and a stop-loss at $105.18 (-5.4%).
That is a reward-to-risk ratio of about 1.0 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Oct 23, 2026 whatever the price does.
Research notes
Halozyme’s bull case rests on rapidly growing ENHANZE royalties, strong partner-drug launches, and potential milestone payments from expanded collaborations; royalty revenue rose 46.7% year over year to $373.8 million in the first half of 2026. The bear case is that the stock’s roughly 63% year-to-date rally and elevated valuation already price in substantial execution, while slower partner launches, pricing pressure, regulatory scrutiny, or competing subcutaneous-delivery platforms could weaken growth. A major recent catalyst is a Dutch court ruling that Merck’s Keytruda SC infringes a Halozyme patent, resulting in an injunction across multiple European markets. Another positive catalyst is the expanded argenx collaboration, which adds two exclusive ENHANZE targets and increases potential future milestones and royalties.
The model's one-paragraph read
Leans BUY — composite score +0.25 (WEAK BUY). Technicals: RSI 41.15, MACD bearish, price above SMA50. Fundamentals: margin 24.9%, revenue growth 47.7%. Financial results: YoY revenue +47.7%, last EPS surprise +25.3%, next earnings 2026-11-02. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bullish order block, price retesting a bearish order block, equal lows below (resting liquidity). FinGPT news read: positive. Internet research: Halozyme’s **bull case** rests on rapidly growing ENHANZE royalties, strong partner-drug launches, and potential milestone payments from expanded collaborations; royalty revenue rose 46.7% year over year to $373.8 million in the first half of 2026. The **bear case** is that the stock’s roughly 63% year-to-date rally and elevated valuation already price in substantial execution, while slower partner launches, pricing pressure, regulatory scrutiny, or competing subcutaneous-delivery platforms could weaken growth. A major recent catalyst is a Dutch court ruling that Merck’s Keytruda SC infringes a Halozyme patent, resulting in an injunction across multiple European markets. Another positive catalyst is the expanded argenx collaboration, which adds two exclusive ENHANZE targets and increases potential future milestones and royalties. Suggested levels: entry $111.21, target $116.94, stop-loss $105.18, exit by 2026-10-23 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for HALO
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 13, 2026 | WEAK BUY | 25% | $111.99 | — |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
HUM · IART · ICLR · IRWD · JNJ · KMDA · LH · LLY · MDT · NRC · NVO · OSCR
Frequently asked questions
Is HALO a buy right now?
As of Oct 13, 2026, our automated model rates Halozyme Therapeutics Inc (HALO) WEAK BUY with 25% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for HALO?
The model's most recent plan targets $116.94 with a stop-loss at $105.18, from an entry near $111.21.
When does Halozyme Therapeutics Inc report earnings next?
The next earnings report is expected around Nov 2, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.